Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

e rapid onset of action."

"Reaching the patient enrollment target in our Phase III clinical trial of Omigard for the prevention of catheter-related infections is a major milestone in our clinical development program for this product candidate," stated James Breitmeyer, M.D., Ph.D., Executive Vice President, Development and Chief Medical Officer of Cadence. "If approved, we believe that Omigard will address a rapidly growing need for more effective ways to lower hospital acquired infection rates, including the dangerous and costly complications from infections related to intravascular catheters."

Cadence's second clinical trial of Acetavance for the treatment of fever in adults, designated Study 303, was a Phase III, randomized, double-blind, double-dummy, single-dose study of intravenous acetaminophen (1 gram) compared to oral acetaminophen (1 gram) for the treatment of fever in 81 adult volunteers with experimentally-induced fever. In this study, a statistically significant difference in favor of Acetavance was observed compared to oral acetaminophen for the primary efficacy endpoint of WSTD2 (the weighted sum of temperature differences over two hours) (p< 0.01). The mean temperature scores for patients in the Acetavance-treated group were significantly lower as early as 15 minutes after the study drug was administered. The peak temperature observed in the Acetavance group of patients was also significantly lower. Acetavance was very well tolerated, including no treatment-emergent serious adverse events or treatment-emergent hepatic adverse events.

Cadence's confirmatory Phase III clinical trial of Omigard (omiganan pentahydrochloride 1% gel), known as the Central Line Infection Reduction Study, or CLIRS, is a randomized, evaluator-blinded study in hospitalized patients whose medical condition requires a short-term central venous catheter. The primary objective of CLIRS is to evaluate the efficacy and safety of Omigard compared to 10% povidone-
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Today, Levi ... new extension to its PageCenterX ® content ... is designed to provide downtime reporting capabilities to ... LRS is releasing the product for general availability, ... EMR applications experience outages for a variety of ...
(Date:7/31/2014)... 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... quarter 2014, on Thursday, August 7, 2014 before markets ... webcast and conference call at 8:00 a.m. Eastern time ... host the call and webcast to discuss financial results ... accessed by calling (800) 708-4540 (domestic) or (847) 619-6397 ...
(Date:7/31/2014)... , July 31 2014  Northsight Capital, Inc. ... has been named Chairman and CEO of the company. ... management, legal matters, business development and investment banking. Mr. ... securities industry.  Before his career on Wall Street, Mr. ... of the U.S, Securities and Exchange Commission in ...
Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Northsight Capital, Inc. Names Wall Street Veteran John Bluher, Former EVP And General Counsel Of Knight Trading Group, Chairman And CEO. 2
... PALO ALTO, Calif., May 3, 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: ... first quarter of 2011. Total revenues for ... to $35.2 million for the first quarter of 2010.  Total ... GAAP net income for the first quarter of 2011 ...
... 3, 2011 Coast Dental Services, Inc., announced today ... the assets of Dental Technology, Inc. (DTI), doing business ... licensed  health care service plan. DTI and its subsidiaries ... Texas, employing 1,200 staff members, including 130 dentists.  The ...
Cached Medicine Technology:Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 2Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 3Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 4Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 5Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 6Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 7Coast Dental to Acquire the Assets of SmileCare 2
(Date:7/31/2014)... OK (PRWEB) July 31, 2014 Shiitakes ... As in the recipe for Quick-Fix Spaghetti Sauce below, ... second-most consumed mushroom worldwide, valued for their deep flavor ... mushrooms. They absorb flavors of the foods they're cooked ... texture and offer high-protein, low-fat nutrition. Shiitakes are rich ...
(Date:7/31/2014)... San Francsico, CA (PRWEB) July 31, 2014 ... in Sweden have published the largest study ... from triage through either teledermoscopy or traditional letter ... indicate that smartphone referrals via patent pending iDoc24® ... of patients with skin cancer while potentially eliminating ...
(Date:7/31/2014)... -- A class of medications previously linked to ... negatively affect their physical functioning according to investigators ... Center for Aging Research, the University of East ... In a systemic review of more than a ... with anticholinergic properties, they report that these drugs ...
(Date:7/31/2014)... 31, 2014 Controlled application of vacuum pressure is ... brain injury (TBI), suggests an experimental study in the ... journal of the Congress of Neurological Surgeons . ... Wilkins , a part of Wolters Kluwer Health ... applied over the injured area of the brainshows promise ...
(Date:7/31/2014)... July 31, 2014 Rivetz Corp. today ... authentication services to cloud service providers. The combined solution ... protected multi-factor authentication with online systems. , There ... password-based authentication. It is the root cause of the ... around the globe. Instead of solving the problem, service ...
Breaking Medicine News(10 mins):Health News:Quick Fixin’ Summertime Meals with Shiitake Mushrooms -- Bring ‘em Home and Grow Your Own 2Health News:Quick Fixin’ Summertime Meals with Shiitake Mushrooms -- Bring ‘em Home and Grow Your Own 3Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 2Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 3Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 4Health News:Common drugs adversely impair older adults' physical as well as cognitive functioning 2Health News:Vacuum treatment may limit damage after traumatic brain injury 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3
... to meet with staff and patients and also to view the ... the opportune moment, the Prime Minister was targeted with questions about ... of the health service. ,To the volley of questions, ... will say it's the end of the NHS or, when you ...
... type 1 or juvenile-onset diabetes also works in a rat ... new report from researchers at Washington University School of Medicine ... 2 diabetes in the same way is very significant because ... prevalent than type 1 diabetes," says senior author Marc R. ...
... Rizal and Marikina City as of Thursday. // ... child from Balanga, Bataan were among its victims,According to ... Center the Valenzuela child was at “critical stage 4,” ... treatment Wednesday. ,Lustre stated that he was ...
... diseases that ails many millions of people in parts ... renewed thrust by The Bill & Melinda Gates Foundation, ... million. ,This fund will assist in controlling ... are spread by parasites and worms. These worms are ...
... Fiancée of England star Wayne Rooney, Coleen McLoughlin launched ... her desire to raise awareness of the work hospices ... much-needed funds.// ,Coleen, 20, has personal experience to ... disorder Rett Syndrome and is a regular visitor to ...
... issue of the British Medical Journal, calcium supplements to kids does ... ,According to the research, 90% of the maximum bone mass ... expected that enhancing bone mass at an early age might reduce ... results of 19 studies, on about 2,900 kids and teens aged ...
Cached Medicine News:Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 2Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 3
... supply is the latest edition ... offering. It sets new standards ... This product has unique features ... as microAmp detector, display and ...
... as a constant voltage power supply, the 105 ... and hilo range switch control the output, which ... 250 volts. One, two-position switch toggles the bright ... current. The 105 is equipped with an over ...
... power supply is capable of producing up to ... product operates in constant voltage or constant current ... crosses over from one mode of operation to ... A dual function, auto ranging 24-hour ...
... designed for horizontal and vertical gel electrophoresis ... accomplished. In this power supply model, output ... or constant voltage. Four sets of output ... simultaneously. This power supply's light, compact and ...
Medicine Products: